JW Pharmaceutical said on the 19th that it registered a patent for the hair loss treatment candidate "JW0061" in the United States. The company said the candidate, which promotes follicle proliferation and hair regeneration, can help with androgenetic alopecia and alopecia areata. It will have exclusive rights in the United States through May 2039.
JW Pharmaceutical has registered patents for the hair loss treatment candidate in nine countries, including the United States, Korea, Japan, China, Australia, and Brazil. Europe and Canada are reviewing the patent applications. In animal preclinical studies, the candidate improved efficacy by up to 39%. The company recently submitted a phase 1 clinical trial plan for JW0061 to the Ministery of Food and Drug Safety.
A JW Pharmaceutical official said it is "a candidate designed based on a mechanism that physiologically activates the hair growth pathway," adding it is "a mechanism differentiated from existing treatments based on male hormone suppression or vasodilation."